Matches in SemOpenAlex for { <https://semopenalex.org/work/W4200225892> ?p ?o ?g. }
Showing items 1 to 69 of
69
with 100 items per page.
- W4200225892 endingPage "S329" @default.
- W4200225892 startingPage "S328" @default.
- W4200225892 abstract "Smoking is associated with high healthcare resource utilisation and cost to society. Patients with major depressive disorder (MDD) exhibit high susceptibility to nicotine dependence. Varenicline, bupropion and nicotine replacement therapy are all indicated for smoking cessation; however funding by the Spanish national health system (SNHS) is limited. We modelled a budgetary impact analysis (BIA) to estimate the impact of the SNHS funding drug-based therapies for smoking cessation in smokers with MDD.The BIA compared the current unfunded scenario versus a funded scenario (varenicline, bupropion, nicotine replacement therapy combined with medical follow-up and counselling) using the Spanish SNHS and societal perspectives. The BIA design was a hybrid model using a decision tree algorithm (population size: smokers with MDD) and Markov chains (smoking cessation attempts) over a 5-year horizon. Smoking cessation drug efficacy was derived from clinical trials, and smoking cessation costs avoided were taken from an analysis of the Spanish National Health Survey. Results were shown as incremental cost savings. Scenarios and threshold univariate sensitivity analyses tested model robustness.The funded scenario resulted in an increase of 43,478 cessation attempts and 8930 fewer smokers after 5 years compared to the unfunded scenario. The cost of funding was €25.3 million and costs avoided were €26.5 million. There was a cumulative 5-year incremental cost saving of €1.2 million to Spanish society. Results were robust using alternative scenarios.Funding smoking cessation drugs in patients with MDD is of economic benefit to Spain and could produce net savings from the third year of implementation." @default.
- W4200225892 created "2021-12-31" @default.
- W4200225892 creator A5006324507 @default.
- W4200225892 creator A5047337562 @default.
- W4200225892 creator A5066111748 @default.
- W4200225892 creator A5071543655 @default.
- W4200225892 creator A5076448957 @default.
- W4200225892 date "2021-12-01" @default.
- W4200225892 modified "2023-10-16" @default.
- W4200225892 title "P.0449 Evaluation of IGF-1 as a novel theranostic biomarker for schizophrenia" @default.
- W4200225892 cites W1515568852 @default.
- W4200225892 cites W2051361265 @default.
- W4200225892 cites W2079878023 @default.
- W4200225892 cites W2137560695 @default.
- W4200225892 cites W2154806883 @default.
- W4200225892 cites W2599306300 @default.
- W4200225892 cites W2982685163 @default.
- W4200225892 cites W4211145950 @default.
- W4200225892 doi "https://doi.org/10.1016/j.euroneuro.2021.10.422" @default.
- W4200225892 hasPublicationYear "2021" @default.
- W4200225892 type Work @default.
- W4200225892 citedByCount "0" @default.
- W4200225892 crossrefType "journal-article" @default.
- W4200225892 hasAuthorship W4200225892A5006324507 @default.
- W4200225892 hasAuthorship W4200225892A5047337562 @default.
- W4200225892 hasAuthorship W4200225892A5066111748 @default.
- W4200225892 hasAuthorship W4200225892A5071543655 @default.
- W4200225892 hasAuthorship W4200225892A5076448957 @default.
- W4200225892 hasConcept C118552586 @default.
- W4200225892 hasConcept C142724271 @default.
- W4200225892 hasConcept C169900460 @default.
- W4200225892 hasConcept C2777053506 @default.
- W4200225892 hasConcept C2777843972 @default.
- W4200225892 hasConcept C2779908668 @default.
- W4200225892 hasConcept C2780051608 @default.
- W4200225892 hasConcept C2780478649 @default.
- W4200225892 hasConcept C2908647359 @default.
- W4200225892 hasConcept C71924100 @default.
- W4200225892 hasConcept C99454951 @default.
- W4200225892 hasConceptScore W4200225892C118552586 @default.
- W4200225892 hasConceptScore W4200225892C142724271 @default.
- W4200225892 hasConceptScore W4200225892C169900460 @default.
- W4200225892 hasConceptScore W4200225892C2777053506 @default.
- W4200225892 hasConceptScore W4200225892C2777843972 @default.
- W4200225892 hasConceptScore W4200225892C2779908668 @default.
- W4200225892 hasConceptScore W4200225892C2780051608 @default.
- W4200225892 hasConceptScore W4200225892C2780478649 @default.
- W4200225892 hasConceptScore W4200225892C2908647359 @default.
- W4200225892 hasConceptScore W4200225892C71924100 @default.
- W4200225892 hasConceptScore W4200225892C99454951 @default.
- W4200225892 hasLocation W42002258921 @default.
- W4200225892 hasOpenAccess W4200225892 @default.
- W4200225892 hasPrimaryLocation W42002258921 @default.
- W4200225892 hasRelatedWork W1974063527 @default.
- W4200225892 hasRelatedWork W2045335964 @default.
- W4200225892 hasRelatedWork W2087896311 @default.
- W4200225892 hasRelatedWork W2188165642 @default.
- W4200225892 hasRelatedWork W2212046962 @default.
- W4200225892 hasRelatedWork W2339388638 @default.
- W4200225892 hasRelatedWork W2416255340 @default.
- W4200225892 hasRelatedWork W2620613230 @default.
- W4200225892 hasRelatedWork W3161741703 @default.
- W4200225892 hasRelatedWork W4229455136 @default.
- W4200225892 hasVolume "53" @default.
- W4200225892 isParatext "false" @default.
- W4200225892 isRetracted "false" @default.
- W4200225892 workType "article" @default.